Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
50 hedge funds and large institutions have $32.7M invested in Odonate Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 19 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 58 → 50 (-8)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
66% less capital invested
Capital invested by funds: $95M → $32.7M (-$62.2M)
88% less call options, than puts
Call options by funds: $7K | Put options by funds: $56K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$707K |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
+$615K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$556K |
| 4 |
D.E. Shaw & Co
New York
|
+$333K |
| 5 |
Renaissance Technologies
New York
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$6.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$3.31M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.18M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.01M |
ODT Hedge Fund Activity: Q4 2021 in Review
50 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q4 2021, worth a combined $32.7M — down 66% from $95M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ODT and 11 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 19 added.
The largest buyer was Prosight Management, opening a new position worth an estimated $707K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.8M sold.
- 50 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q4 2021, down from 58 in Q3 2021.
- Funds reported $32.7M of Odonate Therapeutics, Inc. Common Stock stock for Q4 2021, down 66% quarter-over-quarter.
- 11 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q4 2021 and 19 closed out, a net change of -8 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q4 2021 was Prosight Management, an estimated $707K added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q4 2021 was EcoR1 Capital, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2021.